UNSPSC 51434940: Hydrochlorothiazide/lisinopril

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434940 Hydrochlorothiazide/lisinopril, a Commodity-tier code, covers prescription and over-the-counter medications supplied to state and local government health systems, emergency medical services, and pharmacy benefit programs. State and local governments procure these products through direct medication supply contracts, cooperative purchasing agreements with multistate alliances, and therapeutic pharmacy initiatives. Issuing bodies include city fire rescue departments, state health and human services agencies, and multistate cooperative purchasing organizations administering contracts on behalf of multiple jurisdictions and institutional health plans. The work involves supplying pharmaceutical products with firm pricing, managed inventory and expiration protocols, full compliance documentation including OSHA Safety Data Sheets and FDA manufacturing certifications, and delivery within specified timeframes—typically ten to thirty days.

Recent activity shows geographic spread across Florida, Texas, and Minnesota. The City of Tampa's Purchasing Department issued IFB 26P00188 in April 2026 for Advanced Life Support Medications, with response due April 8, 2026 and an estimated contract value of $40,000, sheltered under a Small Local Business Enterprise designation with a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 seeking vendor capabilities for a Direct-to-Manufacturer Prescriptions program—an exploratory phase before formal procurement to assess vendor capacity for direct contracting outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 with response due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring vendors to work through three authorized wholesalers and maintain comprehensive insurance and manufacturing compliance.